Concepedia

Complement deficiencies limit CD20 monoclonal antibody treatment efficacy in CLL

Odette Middleton, Emilio Cosimo, Edwina Dobbin, Alison M. McCaig, C. Peter Clarke, Alison Brant, Mike Leach, Alison M. Michie, Helen Wheadon

Leukemia · 2014 · 78 citations · 26 references

DOI

Concepts

References

26

Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial

Michael Hallek, Kirsten Fischer, Guenter Fingerle-Rowson et al. · The Lancet · 2010 · 1.9K citations

, , +10

Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial

Daniel Catovsky, Estella Matutes, R. F. Bezares et al. · The Lancet · 2007 · 679 citations

, , +13

Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas

Jessica L. Teeling · Blood · 2004 · 627 citations · Full text

, , +16

The Biological Activity of Human CD20 Monoclonal Antibodies Is Linked to Unique Epitopes on CD20

Jessica L. Teeling, Wendy J.M. Mackus, Luus Wiegman et al. · The Journal of Immunology · 2006 · 604 citations

, , +17

Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial

Patrick J. Loehrer · Yearbook of Oncology · 2008 · 602 citations

, , +13